Pharmaceuticals
How the pharma industry works, and the finance, marketing, data and AI that run it.
The programs
Five programs, one per domain of the Pharmaceuticals sector. Every one is readable straight away, without an account, and you can gauge your level on any of them whenever you want.
Pharmaceuticals
This block gives you the operating logic of the pharmaceutical industry, from molecule discovery to patient access.
16 lessons · about 3h
- Map the pharmaceutical value chain from discovery through post-market surveillance and identify where value and risk concentrate
- Explain the competitive dynamics between originators, generics, biosimilars and payers, and how power and margin shift across the chain
- Identify which regulations (FDA, EMA, GxP, IP law) apply to a given business decision and what compliance it requires
Finance for Pharmaceuticals
Pharmaceutical finance runs on a distinct economic model: enormous upfront R&D spend, long development timelines, patent-driven revenue cliffs, and asymmetric risk-reward across a drug pipeline.
27 lessons · about 5h
- Map the pharmaceutical value chain from discovery through post-market surveillance and identify where value and risk concentrate
- Explain the competitive dynamics between originators, generics, biosimilars and payers, and how power and margin shift across the chain
- Identify which regulations (FDA, EMA, GxP, IP law) apply to a given business decision and what compliance it requires
Marketing for Pharmaceuticals
Pharmaceutical marketing operates under constraints unlike any other industry: prescribers, not patients, often drive purchase decisions, and promotional activity is tightly policed by regulators and payers.
27 lessons · about 5h
- Map the pharmaceutical value chain from discovery through post-market surveillance and identify where value and risk concentrate
- Explain the competitive dynamics between originators, generics, biosimilars and payers, and how power and margin shift across the chain
- Identify which regulations (FDA, EMA, GxP, IP law) apply to a given business decision and what compliance it requires
Data for Pharmaceuticals
Pharmaceutical decision-making rests on data spanning drug discovery, clinical trials, regulatory submissions, manufacturing, and commercial performance.
27 lessons · about 5h
- Map the pharmaceutical value chain from discovery through post-market surveillance and identify where value and risk concentrate
- Explain the competitive dynamics between originators, generics, biosimilars and payers, and how power and margin shift across the chain
- Identify which regulations (FDA, EMA, GxP, IP law) apply to a given business decision and what compliance it requires
AI for Pharmaceuticals
AI is reshaping pharmaceuticals across drug discovery, clinical trials, manufacturing and commercial operations, but the sector's regulatory intensity, safety obligations and data complexity demand a distinct approach to adoption.
27 lessons · about 5h
- Map the pharmaceutical value chain from discovery through post-market surveillance and identify where value and risk concentrate
- Explain the competitive dynamics between originators, generics, biosimilars and payers, and how power and margin shift across the chain
- Identify which regulations (FDA, EMA, GxP, IP law) apply to a given business decision and what compliance it requires
Pharmaceuticals is one of the most distinctive industries there is: extreme R&D risk, long regulated timelines, and business rules that override the instincts you built elsewhere. This vertical gives you the sector's big picture, then how finance, marketing, data and AI each work inside it.
Key terms
Why specialize in Pharmaceuticals?
Cross-cutting skills are not enough in the Pharmaceuticals sector. It plays by its own rules: a distinct value chain, specific players and balance of power, dense regulation, and key figures you won't find anywhere else. This vertical gives you that sector fluency: first the big picture, then finance, marketing, data and AI applied concretely to Pharmaceuticals, with the calculations, benchmarks and checklists you actually need on the ground.
What you'll be able to do
- Understand how the Pharmaceuticals sector works: value chain, key players and balance of power
- Know the major regulations and laws, the sector's acronyms and vocabulary
- Run the key calculations and read the benchmarks specific to Pharmaceuticals (US and Europe markets)
- Apply finance, marketing, data and AI to the realities of Pharmaceuticals
- Gauge your level with 5 sector assessments and a competency radar
60 lessons across 16 modules and 5 blocks, with a test per lens and a sector competency radar. Free to read, no account required.
The curriculum in detail
Pharma: how the sector works
GeneralThe pharmaceutical value chain end to end: discovery, clinical trials, approval, manufacturing, and commercialization, plus who the players are and how money is made.
4 Modules · 16 Lessons
Finance in pharma
FinanceWhat makes pharma finance distinctive: R&D as a risky capital allocation, patent-cliff revenue dynamics, pricing and reimbursement, and how the numbers differ from other industries.
3 Modules · 11 Lessons
Marketing in pharma
MarketingMarketing a product where most rules from other industries do not apply: heavy regulation, HCP vs patient audiences, medical affairs, market access, and launch excellence.
3 Modules · 11 Lessons
Data in pharma
DataThe data that runs pharma, from clinical trials to real-world evidence, and the strict governance (GxP, privacy) that makes pharma data unlike data anywhere else.
3 Modules · 11 Lessons
AI in pharma
AIWhere AI genuinely helps across the pharma value chain, from drug discovery to pharmacovigilance, and the regulatory reality that shapes what you can actually deploy.
3 Modules · 11 Lessons
Prefer to place yourself first?
Five short assessments, one per domain of the Pharmaceuticals sector. Ten questions each, three minutes, and a competency radar once you have taken more than one.
All sector assessmentsLatest articles
What the blog publishes on Pharmaceuticals, across every discipline.
- FinancePharma partnership terms that protect your pipeline when the science goes sidewaysMilestone-based deals are how most biotech companies survive long enough to see their drug approved, but poorly structured agreements can leave a CFO holding the downside while the partner captures the upside. This playbook shows how to build deal terms that align incentives across a decade-long development arc.
- DataOne HCP, six records: why identity resolution is pharma's most expensive data problemA single cardiologist can exist as six different entities across a pharma company's CRM, claims data, and prescriber analytics systems, and none of them match. Until identity resolution works in practice, every downstream decision, from sampling allocations to pharmacovigilance reporting, is built on a fractured foundation.
- FinanceRisk-adjusted NPV for pre-revenue biotech pipelines: how the math actually worksMost valuation frameworks break down when applied to a drug candidate that has never generated a dollar of revenue and may never reach patients. Risk-adjusted NPV fixes that problem, but only if you understand what the model is actually doing and where it quietly fails.
- DataGxP integrity, 21 CFR Part 11, and GDPR: what happens when three regulatory regimes collidePharma CDOs operate at the intersection of three distinct regulatory systems, each with its own logic, its own enforcement body, and its own definition of what a data record actually is. Understanding where those systems conflict, not just where they overlap, is the difference between audit readiness and a consent notice architecture that accidentally destroys your audit trail.
- DataPrivacy-enhancing technologies in practice: the hype is ahead of the implementationPrivacy-enhancing technologies have generated serious boardroom attention, and the underlying science is real. But the gap between pilot programs and production-grade deployment is wider than most CDOs are being told.
Frequently asked questions
What does this pharmaceuticals vertical actually cover?
It covers five blocks: how the pharma sector works end to end, then finance, marketing, data and AI as each is practised inside pharma. The first block walks the value chain from discovery and clinical trials through approval, manufacturing and commercialization, including who the players are and where the money comes from.
Who is it for if I have never worked in pharma?
It suits anyone arriving from another industry with solid finance, marketing or data skills and no pharma context: consultants, investors, new joiners in a lab or a medtech, or executives taking on a healthcare portfolio. The premise is that pharma's business rules override instincts built elsewhere, so the sector overview comes before the functional blocks.
Where should I start if I only have time for one block?
Start with "Pharma: how the sector works". Discovery, clinical trials, approval, manufacturing and commercialization form the backbone that the finance, marketing, data and AI blocks all refer back to. Reading a functional block first works, but you will keep coming back for the timeline and the regulatory context.
Do I get a diploma or a certification at the end?
No. There is no diploma, no state-recognised certification and no affiliation with a school or a university. Reading is open and free; an account only saves where you left off.
What makes pharma finance different from finance in other industries?
R&D behaves as risky capital allocation rather than a routine cost line, revenue follows patent-cliff dynamics instead of a smooth curve, and prices depend on reimbursement decisions rather than on what the market will bear. The finance block explains how those three factors reshape the numbers you read in a pharma company's accounts.
Why can't I reuse my usual marketing playbook in pharma?
Because most of it is either illegal or irrelevant there. Pharma marketing splits between HCP and patient audiences under heavy regulation, and leans on medical affairs and market access, functions that have no equivalent in consumer marketing. The marketing block also covers launch excellence, where a large share of a drug's lifetime value is decided in the first months.
What is real-world evidence and how does it differ from clinical trial data?
Clinical trial data comes from a controlled protocol with selected patients; real-world evidence comes from routine care, so claims registries, electronic records and observational follow-up. Both feed pharma decisions, and both fall under strict governance, GxP requirements and privacy rules, which the data block treats as a core constraint rather than a footnote.
Which AI use cases in pharma are real rather than demos?
The AI block sorts genuine uses across the value chain, from drug discovery at the research end to pharmacovigilance on the safety side, and states the regulatory reality that decides what can actually be deployed. In a GxP environment, validation and traceability requirements rule out many models that would ship without objection elsewhere.